A Sonographic Lesion Index for Crohn's Disease Helps Monitor Changes in Transmural Bowel Damage During Therapy

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 12, 2014, Pages 2071-2077

  Zorzi, Francesca ^a   Stasi, Elisa ^a   Bevivino, Gerolamo ^a   Scarozza, Patrizio ^a   Biancone, Livia ^a   Zuzzi, Sara ^a   Rossi, Carla ^a   Pallone, Francesco ^a   Calabrese, Emma ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Anti TNF ; Crohn's Disease; Drug Monitoring; SICUS; Transmural Bowel Damage

Indexed keywords

MESALAZINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CROHN DISEASE; ECHOGRAPHY; FEMALE; HUMAN; IMAGE ANALYSIS; MAINTENANCE THERAPY; MALE; MIDDLE AGED; PROSPECTIVE STUDY; REMISSION; SONOGRAPHIC LESION INDEX FOR CROHN DISEASE; TREATMENT OUTCOME; CHILD; DRUG MONITORING; EVALUATION STUDY; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; SMALL INTESTINE; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CROHN DISEASE; DRUG MONITORING; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTESTINE, SMALL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84918842922     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.04.036     Document Type: Article

References (21)

1. Froslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
2. Solberg I.C., Lygren I., Jahnsen J., et al. Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease. Gut 2008, 57:A15.
3. Baert F., Moortgat L., Van Assche G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
4. Schnitzler F., Fidder H., Ferrante M., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
5. Panes J., Bouhnik Y., Reinisch W., et al. imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. JCrohns Colitis 2013, 7:556-585.
6. Panés J., Bouzas R., Chaparro M., et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 2011, 34:125-145.
7. Bruining D.H., Loftus E.V., Ehman E.C., et al. Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011, 9:679-683.
8. Van Assche G., Herrmann K.A., Louis E., et al. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. JCrohns Colitis 2013, 7:950-957.
9. Castiglione F., Testa A., Rea M., et al. Transmural healing evaluated by bowel sonography in patients with Crohn's disease on maintenance treatment with biologics. Inflamm Bowel Dis 2013, 19:1928-1934.
10. Ordàs I., Rimola J., Rodrìguez S., et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology 2014, 146:374-382.
11. Calabrese E., Zorzi F., Zuzzi S., et al. Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn's disease. JCrohns Colitis 2012, 6:852-860.
12. Dignass A., Van Assche G., Lindsay J.O., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. JCrohns Colitis 2010, 4:28-62.
13. Allez M., Karmiris K., Louis E., et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. JCrohns Colitis 2010, 4:356-366.
14. Best W.R., Becktel J.M., Singleton J.W. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979, 77:843-846.
15. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers inIBD: useful, magic, or unnecessary toys?. Gut 2006, 55:426-431.
16. Calabrese E., Zorzi F., Pallone F. Ultrasound in Crohn's disease. Curr Drug Targets 2012, 13:1224-1233.
17. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19:5-36.
18. Panaccione R., Colombel J.F., Peyrin-Biroulet L., et al. Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis 2013, 19:1645-1653.
19. Colombel J.F., Louis E., Peyrin-Biroulet L., et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014, 12:414-422.
20. Colombel J.F., Louis E., Peyrin-Biroulet L., et al. Deep remission: a new concept?. Dig Dis 2012, 30:107-111.
21. Peloquin J.M., Pardi D.S., Sandborn W.J., et al. Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2008, 103:2015-2022.